Most people diagnosed with Friedreich ataxia are concerned about their communication, rating speech one of the most important features of the disease requiring treatment (Food and Drug Administration (FDA) Externally-led Patient-Focused Drug Development Meeting, 2017). Dysarthria and dysphonia are highly prevalent in hereditary ataxia, worsening with disease progression. Impairments impact all speech subsystems rendering speech slow, unclear and difficult to understand.

Redenlab’s speech tests are designed to enhance a sponsor’s ability to make decisions about the efficacy of their therapies. We use objective markers of speech to capture change in disease and communication, adding value to trial clinical endpoints.